Gemcitabine in the Second-Line Therapy of Patients with Carcinoma of Unknown Primary Site: A Phase II Trial of the Minnie Pearl Cancer Research Network-Reference-Cited by-同舟云学术

Gemcitabine in the Second-Line Therapy of Patients with Carcinoma of Unknown Primary Site: A Phase II Trial of the Minnie Pearl Cancer Research Network

Published:2001-01 Issue:4 Volume:19 Page:335-339
ISSN:0735-7907
Container-title:Cancer Investigation
language:en
Short-container-title:Cancer Investigation

Author:

Hainsworth John D.,Burris Howard A.,Calvert Sharon W.,Willcutt Noel T.,Scullin Daniel C.,Bramham Jane,Greco F. Anthony

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,General Medicine

Link

http://www.tandfonline.com/doi/pdf/10.1081/CNV-100103127

Reference16 articles.

1. Treatment of the patient with adenocarcinoma of unknown origin

2. 5-fluorouracil, adriamycin, and mitomycin in the treatment of adenocarcinoma of unknown primary.

3. Continuous infusion 5-fluorouracil, etoposide and cis-diamminedichloro platinum in patients with metastatic carcinoma of unknown primary origin

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial;Nature Communications;2023-10-24

2. Neoplasms of Unknown Primary Site;Holland‐Frei Cancer Medicine;2022-10-21

3. A multicentre retrospective study comparing site-specific treatment with empiric treatment for unfavourable subset of cancer of unknown primary site;Japanese Journal of Clinical Oncology;2022-09-01

4. Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial;Journal for ImmunoTherapy of Cancer;2022-05

5. Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary;Annals of Oncology;2022-02